University of Arkansas
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Arkansas sits in the top decile of US sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count).
University of Arkansas: 318 sponsored US clinical trials, 37 recruiting.
University of Arkansas sponsors 318 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 202 completed. 17 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 15 trials.
Top-decile sponsor footprint
University of Arkansas ranks in the top decile of sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
202 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
318 total, page 3 of 7
Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa
NCT04600375
Treatment of POEMS Syndrome With Daratumumab
NCT04396496
Written vs Electronic Safety Planning Study
NCT04026308
Plasma Concentration of Biological Markers in Placenta Accreta Spectrum
NCT04525534
Preoperative SRS/SRT vs Postoperative SRS/SRT for Brain Metastases
NCT04422639
Impact of COVID-19 on Marshallese Communities in the U.S.
NCT04474496
Fetal Exposure to Cannabinoids: Exposure, Methylation and Neurodevelopmental Effects
NCT04422600
Reducing Tobacco Exposures Among African American Women and Children
NCT03476837
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
NCT03821272
The Acceptability and Feasibility of an ED-based, Peer-delivered, Suicide Safety Planning Intervention
NCT04068142
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
NCT04064567
Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers
NCT04896502
Leveraging Implementation Science to Increase Access to Trauma Treatment for Incarcerated Drug Users
NCT04007666
Dural Puncture Epidural Versus Epidural Anesthesia for Cesarean Delivery
NCT03915574
Video-based, Patient-Focused Opioid Education in the Perioperative Period
NCT03986866
Building Partnerships With First Responders to Improve Delivery and Access of Mental Health Services
NCT03801408
Utilizing Technology to Promote Cancer Prevention
NCT03810053
Plasma Concentration of Biological Markers in Placental Abruption
NCT03782168
Vaccination of Triple Negative Breast Cancer Patients
NCT02938442
Chronic Kidney Disease (CKD) Platelet Study
NCT03649711
An Analysis of the Outcomes From Protocolized Perioperative Care for Patients Receiving Total Hip or Knee Arthroplasty
NCT03071250
Healthy Body Healthy Souls in the Marshallese Population
NCT03377244
Narcotic Free TIVA and Incidence of Unacceptable Movements Under Anesthesia During ACDF Surgery
NCT03643796
(KIWI) Speeding up a Slow Protein for Muscle Mass With Hay Kiwifruit
NCT04356573
Effect of an EAA/Whey Composition on Protein Metabolism
NCT03502941
Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC
NCT03552965
Nutritional Therapy Interventions in Heart Failure
NCT03424265
Comparison of Chloroprocaine vs Lidocaine for Epidural Anesthesia in Cesarean Delivery
NCT03414359
Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease
NCT03356990
Direct Peritoneal Resuscitation in Gastroschisis
NCT03205553
Developing and Testing Implementation Strategies for Evidence-Based Obesity Prevention in Childcare
NCT03075085
Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population
NCT03270436
Novel Virtual Reality for Burn Wound Care Pain in Adolescents
NCT03155607
Computerized Assessment and Referral System Screener for Mental Health Evaluations in the Emergency Setting
NCT03323853
"Ounce-equivalents" in the Protein Foods Group: Benefits of Quality
NCT03179462
Regulating Homeostatic Plasticity and the Physiological Response to rTMS
NCT03309696
Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
NCT03299062
Manikin To Patient Intubation: Does It Translate?
NCT03046966
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
NCT03110900
Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity
NCT03139318
Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)
NCT03083132
Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients
NCT02693743
Are the "ounce-equivalents" in the Protein Foods Groups Really Equivalent?
NCT03142737
Health Literacy Intervention to Improve Diabetes Outcomes Among Rural Primary Care Patients
NCT02779556
Cosmetology Students and Skin Cancer
NCT03673917
ssTAP vs TAP Catheters in TAH
NCT02525900
Mitochondrial Function in Circulating Cells and Muscle Tissue
NCT02700698
Nutritional Therapy for Autonomic Dysfunction in Elderly Heart Failure Patients
NCT06256276
Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
NCT02696759
Movement Assessment for Concussion Management
NCT02776904
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 40 |
| Phase 2 | 62 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the University of Arkansas pipeline
37 recruiting of 318 indexed (12% open); 202 completed (64%).
Phase mix: 17 late (III/IV) vs 102 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Arkansas: open-pipeline peers nationwide
Peers matched on 318 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
University of Arkansas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 318 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
- Allergan · 314 trials · 0% recruiting
- Celgene · 308 trials · 4% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Jazz Pharmaceuticals · 12% recruiting · 128 trials
- Abbott Diabetes Care · 12% recruiting · 26 trials
- Medtronic Vascular · 12% recruiting · 26 trials
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
Related
What to do with this University of Arkansas page
318 registered trials is a research-attention snapshot, not an endorsement of University of Arkansas or any single study.
- 37 of University of Arkansas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition University of Arkansas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Arkansas pipeline card: 318 registered trials from official public datasets.Report a data error.